Research ExplorerPublicationsCost-effectiveness of stimulation of the sphenopalatine gang...

Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study

Standard

Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study. / Pietzsch, Jan B; Garner, Abigail; Gaul, Charly; May, Arne.

In: J HEADACHE PAIN, Vol. 16, 21.05.2015, p. 530.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Pietzsch, JB, Garner, A, Gaul, C & May, A 2015, 'Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study', J HEADACHE PAIN, vol. 16, pp. 530. https://doi.org/10.1186/s10194-015-0530-8

APA

Pietzsch, J. B., Garner, A., Gaul, C., & May, A. (2015). Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study. J HEADACHE PAIN, 16, 530. https://doi.org/10.1186/s10194-015-0530-8

Vancouver

Pietzsch JB, Garner A, Gaul C, May A. Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study. J HEADACHE PAIN. 2015 May 21;16:530. https://doi.org/10.1186/s10194-015-0530-8

Bibtex

@article{ec99184009c04ba18477d249b8e16e5b,
title = "Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study",
abstract = "BACKGROUND: In the recent Pathway CH-1 study, on-demand stimulation of the sphenopalatine ganglion (SPG) by means of an implantable neurostimulation system was proven to be a safe and effective therapy for the treatment of chronic cluster headache. Our objective was to assess the cost-effectiveness of SPG stimulation in the German healthcare system when compared to medical management.METHODS: Clinical data from the Pathway CH-1 study were used as input for a model-based projection of the cost-effectiveness of SPG stimulation through 5 years. Medical management as the comparator treatment was modeled on the basis of clinical events observed during the baseline period of CH-1. The costs of treatment were derived from a previously published cluster headache costing study and 2014 medication, neurostimulator, and procedure costs. We computed the 5-year incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY), with costs and effects discounted at 3 % per year.RESULTS: SPG stimulation was projected to add 0.325 QALYs over the study period, while adding €889 in cost, resulting in a 5-year ICER of €2,736 per QALY gained. Longer follow-up periods, higher baseline attack frequency, and higher utilization of attack-aborting medications led to overall cost savings. SPG stimulation was found either cost-effective or cost-saving across all scenarios investigated in sensitivity analyses.CONCLUSIONS: Our model-based analysis suggests that SPG stimulation for the treatment of chronic cluster headache, under the assumption of sustained therapy effectiveness, leads to meaningful gains in health-related quality of life and is a cost-effective treatment strategy in the German healthcare system.",
keywords = "Adult, Cluster Headache, Cost-Benefit Analysis, Electric Stimulation Therapy, Electrodes, Implanted, Female, Ganglia, Parasympathetic, Health Care Costs, Humans, Male, Middle Aged, Pterygopalatine Fossa, Quality-Adjusted Life Years, Treatment Outcome, Young Adult",
author = "Pietzsch, {Jan B} and Abigail Garner and Charly Gaul and Arne May",
year = "2015",
month = may,
day = "21",
doi = "10.1186/s10194-015-0530-8",
language = "English",
volume = "16",
pages = "530",
journal = "J HEADACHE PAIN",
issn = "1129-2369",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study

AU - Pietzsch, Jan B

AU - Garner, Abigail

AU - Gaul, Charly

AU - May, Arne

PY - 2015/5/21

Y1 - 2015/5/21

N2 - BACKGROUND: In the recent Pathway CH-1 study, on-demand stimulation of the sphenopalatine ganglion (SPG) by means of an implantable neurostimulation system was proven to be a safe and effective therapy for the treatment of chronic cluster headache. Our objective was to assess the cost-effectiveness of SPG stimulation in the German healthcare system when compared to medical management.METHODS: Clinical data from the Pathway CH-1 study were used as input for a model-based projection of the cost-effectiveness of SPG stimulation through 5 years. Medical management as the comparator treatment was modeled on the basis of clinical events observed during the baseline period of CH-1. The costs of treatment were derived from a previously published cluster headache costing study and 2014 medication, neurostimulator, and procedure costs. We computed the 5-year incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY), with costs and effects discounted at 3 % per year.RESULTS: SPG stimulation was projected to add 0.325 QALYs over the study period, while adding €889 in cost, resulting in a 5-year ICER of €2,736 per QALY gained. Longer follow-up periods, higher baseline attack frequency, and higher utilization of attack-aborting medications led to overall cost savings. SPG stimulation was found either cost-effective or cost-saving across all scenarios investigated in sensitivity analyses.CONCLUSIONS: Our model-based analysis suggests that SPG stimulation for the treatment of chronic cluster headache, under the assumption of sustained therapy effectiveness, leads to meaningful gains in health-related quality of life and is a cost-effective treatment strategy in the German healthcare system.

AB - BACKGROUND: In the recent Pathway CH-1 study, on-demand stimulation of the sphenopalatine ganglion (SPG) by means of an implantable neurostimulation system was proven to be a safe and effective therapy for the treatment of chronic cluster headache. Our objective was to assess the cost-effectiveness of SPG stimulation in the German healthcare system when compared to medical management.METHODS: Clinical data from the Pathway CH-1 study were used as input for a model-based projection of the cost-effectiveness of SPG stimulation through 5 years. Medical management as the comparator treatment was modeled on the basis of clinical events observed during the baseline period of CH-1. The costs of treatment were derived from a previously published cluster headache costing study and 2014 medication, neurostimulator, and procedure costs. We computed the 5-year incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY), with costs and effects discounted at 3 % per year.RESULTS: SPG stimulation was projected to add 0.325 QALYs over the study period, while adding €889 in cost, resulting in a 5-year ICER of €2,736 per QALY gained. Longer follow-up periods, higher baseline attack frequency, and higher utilization of attack-aborting medications led to overall cost savings. SPG stimulation was found either cost-effective or cost-saving across all scenarios investigated in sensitivity analyses.CONCLUSIONS: Our model-based analysis suggests that SPG stimulation for the treatment of chronic cluster headache, under the assumption of sustained therapy effectiveness, leads to meaningful gains in health-related quality of life and is a cost-effective treatment strategy in the German healthcare system.

KW - Adult

KW - Cluster Headache

KW - Cost-Benefit Analysis

KW - Electric Stimulation Therapy

KW - Electrodes, Implanted

KW - Female

KW - Ganglia, Parasympathetic

KW - Health Care Costs

KW - Humans

KW - Male

KW - Middle Aged

KW - Pterygopalatine Fossa

KW - Quality-Adjusted Life Years

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1186/s10194-015-0530-8

DO - 10.1186/s10194-015-0530-8

M3 - SCORING: Journal article

C2 - 26002638

VL - 16

SP - 530

JO - J HEADACHE PAIN

JF - J HEADACHE PAIN

SN - 1129-2369

ER -